Patient-reported outcome instruments for assessing Raynaud’s phenomenon in systemic sclerosis

A SCTC vascular working group report

John D. Pauling, Tracy M. Frech, Michael Hughes, Jessica K. Gordon, Robyn T. Domsic, Marina E. Anderson, Francesca Ingegnoli, Neil J. McHugh, Sindhu R. Johnson, Marie Hudson, Francesco Boin, Voon H. Ong, Marco Matucci-Cerinic, Nezam Altorok, Marina Scolnik, Mandana Nikpour, Ankoor Shah, Janet E. Pope, Dinesh Khanna, Ariane L. Herrick

Research output: Contribution to journalArticle

4 Citations (Scopus)
17 Downloads (Pure)

Abstract

The episodic nature of Raynaud’s phenomenon in systemic sclerosis has led to a reliance on patient-reported outcome instruments such as the Raynaud’s Condition Score diary. Little is known about the utilization in routine clinical practice and health professional attitudes toward existing patient-reported outcome instruments for assessing systemic sclerosis- Raynaud’s phenomenon. Members of the Scleroderma Clinical Trials Consortium Vascular Working Group (n = 28) were invited to participate in a survey gauging attitudes toward the Raynaud’s Condition Score diary and the perceived need for novel patient-reported outcome instruments for assessing patient-reported outcome. Nineteen Scleroderma Clinical Trials Consortium Vascular Working Group members (68% response rate) from academic units based in North America (n = 9), Europe (n = 8), South America (n = 1) and Australasia (n = 1) took part in the survey. There was broad consensus that Raynaud’s Condition Score diary returns could be influenced by factors including seasonal variation in weather, efforts made by patients to avoid or ameliorate attacks of Raynaud’s phenomenon, habituation to Raynaud’s phenomenon symptoms, evolution of Raynaud’s phenomenon symptom characteristics with progressive obliterative microangiopathy, patient-coping strategies, respondent burden and placebo effect. There was consensus that limitations of the Raynaud’s Condition Score diary might be a barrier to drug development (79% of respondents agree/strongly agree) and that a novel patient-reported outcome instrument for assessing systemic sclerosis-Raynaud’s phenomenon should be developed with the input of both clinicians and patients (84% agree/strongly agree). Perceived potential limitations of the Raynaud’s Condition Score diary have been identified along with concerns that such factors might impede drug development programs for systemic sclerosis-Raynaud’s phenomenon. There is support within the systemic sclerosis community for the development of a novel patient-reported outcome instrument for assessing systemic sclerosis-Raynaud’s phenomenon.

Original languageEnglish
Pages (from-to)249-252
Number of pages4
JournalJournal of Scleroderma and Related Disorders
Volume3
Issue number3
Early online date24 May 2018
DOIs
Publication statusPublished - 1 Oct 2018

Keywords

  • Patient-reported outcomes
  • Raynaud’s phenomenon
  • Scleroderma
  • Survey
  • Systemic sclerosis

ASJC Scopus subject areas

  • Immunology and Allergy
  • Rheumatology
  • Immunology

Cite this

Patient-reported outcome instruments for assessing Raynaud’s phenomenon in systemic sclerosis : A SCTC vascular working group report. / Pauling, John D.; Frech, Tracy M.; Hughes, Michael; Gordon, Jessica K.; Domsic, Robyn T.; Anderson, Marina E.; Ingegnoli, Francesca; McHugh, Neil J.; Johnson, Sindhu R.; Hudson, Marie; Boin, Francesco; Ong, Voon H.; Matucci-Cerinic, Marco; Altorok, Nezam; Scolnik, Marina; Nikpour, Mandana; Shah, Ankoor; Pope, Janet E.; Khanna, Dinesh; Herrick, Ariane L.

In: Journal of Scleroderma and Related Disorders, Vol. 3, No. 3, 01.10.2018, p. 249-252.

Research output: Contribution to journalArticle

Pauling, JD, Frech, TM, Hughes, M, Gordon, JK, Domsic, RT, Anderson, ME, Ingegnoli, F, McHugh, NJ, Johnson, SR, Hudson, M, Boin, F, Ong, VH, Matucci-Cerinic, M, Altorok, N, Scolnik, M, Nikpour, M, Shah, A, Pope, JE, Khanna, D & Herrick, AL 2018, 'Patient-reported outcome instruments for assessing Raynaud’s phenomenon in systemic sclerosis: A SCTC vascular working group report', Journal of Scleroderma and Related Disorders, vol. 3, no. 3, pp. 249-252. https://doi.org/10.1177/2397198318774307
Pauling, John D. ; Frech, Tracy M. ; Hughes, Michael ; Gordon, Jessica K. ; Domsic, Robyn T. ; Anderson, Marina E. ; Ingegnoli, Francesca ; McHugh, Neil J. ; Johnson, Sindhu R. ; Hudson, Marie ; Boin, Francesco ; Ong, Voon H. ; Matucci-Cerinic, Marco ; Altorok, Nezam ; Scolnik, Marina ; Nikpour, Mandana ; Shah, Ankoor ; Pope, Janet E. ; Khanna, Dinesh ; Herrick, Ariane L. / Patient-reported outcome instruments for assessing Raynaud’s phenomenon in systemic sclerosis : A SCTC vascular working group report. In: Journal of Scleroderma and Related Disorders. 2018 ; Vol. 3, No. 3. pp. 249-252.
@article{552bb02106784f6a8108ba0574c67bb1,
title = "Patient-reported outcome instruments for assessing Raynaud’s phenomenon in systemic sclerosis: A SCTC vascular working group report",
abstract = "The episodic nature of Raynaud’s phenomenon in systemic sclerosis has led to a reliance on patient-reported outcome instruments such as the Raynaud’s Condition Score diary. Little is known about the utilization in routine clinical practice and health professional attitudes toward existing patient-reported outcome instruments for assessing systemic sclerosis- Raynaud’s phenomenon. Members of the Scleroderma Clinical Trials Consortium Vascular Working Group (n = 28) were invited to participate in a survey gauging attitudes toward the Raynaud’s Condition Score diary and the perceived need for novel patient-reported outcome instruments for assessing patient-reported outcome. Nineteen Scleroderma Clinical Trials Consortium Vascular Working Group members (68{\%} response rate) from academic units based in North America (n = 9), Europe (n = 8), South America (n = 1) and Australasia (n = 1) took part in the survey. There was broad consensus that Raynaud’s Condition Score diary returns could be influenced by factors including seasonal variation in weather, efforts made by patients to avoid or ameliorate attacks of Raynaud’s phenomenon, habituation to Raynaud’s phenomenon symptoms, evolution of Raynaud’s phenomenon symptom characteristics with progressive obliterative microangiopathy, patient-coping strategies, respondent burden and placebo effect. There was consensus that limitations of the Raynaud’s Condition Score diary might be a barrier to drug development (79{\%} of respondents agree/strongly agree) and that a novel patient-reported outcome instrument for assessing systemic sclerosis-Raynaud’s phenomenon should be developed with the input of both clinicians and patients (84{\%} agree/strongly agree). Perceived potential limitations of the Raynaud’s Condition Score diary have been identified along with concerns that such factors might impede drug development programs for systemic sclerosis-Raynaud’s phenomenon. There is support within the systemic sclerosis community for the development of a novel patient-reported outcome instrument for assessing systemic sclerosis-Raynaud’s phenomenon.",
keywords = "Patient-reported outcomes, Raynaud’s phenomenon, Scleroderma, Survey, Systemic sclerosis",
author = "Pauling, {John D.} and Frech, {Tracy M.} and Michael Hughes and Gordon, {Jessica K.} and Domsic, {Robyn T.} and Anderson, {Marina E.} and Francesca Ingegnoli and McHugh, {Neil J.} and Johnson, {Sindhu R.} and Marie Hudson and Francesco Boin and Ong, {Voon H.} and Marco Matucci-Cerinic and Nezam Altorok and Marina Scolnik and Mandana Nikpour and Ankoor Shah and Pope, {Janet E.} and Dinesh Khanna and Herrick, {Ariane L.}",
year = "2018",
month = "10",
day = "1",
doi = "10.1177/2397198318774307",
language = "English",
volume = "3",
pages = "249--252",
journal = "Journal of Scleroderma and Related Disorders",
issn = "2397-1983",
publisher = "Sage Publications",
number = "3",

}

TY - JOUR

T1 - Patient-reported outcome instruments for assessing Raynaud’s phenomenon in systemic sclerosis

T2 - A SCTC vascular working group report

AU - Pauling, John D.

AU - Frech, Tracy M.

AU - Hughes, Michael

AU - Gordon, Jessica K.

AU - Domsic, Robyn T.

AU - Anderson, Marina E.

AU - Ingegnoli, Francesca

AU - McHugh, Neil J.

AU - Johnson, Sindhu R.

AU - Hudson, Marie

AU - Boin, Francesco

AU - Ong, Voon H.

AU - Matucci-Cerinic, Marco

AU - Altorok, Nezam

AU - Scolnik, Marina

AU - Nikpour, Mandana

AU - Shah, Ankoor

AU - Pope, Janet E.

AU - Khanna, Dinesh

AU - Herrick, Ariane L.

PY - 2018/10/1

Y1 - 2018/10/1

N2 - The episodic nature of Raynaud’s phenomenon in systemic sclerosis has led to a reliance on patient-reported outcome instruments such as the Raynaud’s Condition Score diary. Little is known about the utilization in routine clinical practice and health professional attitudes toward existing patient-reported outcome instruments for assessing systemic sclerosis- Raynaud’s phenomenon. Members of the Scleroderma Clinical Trials Consortium Vascular Working Group (n = 28) were invited to participate in a survey gauging attitudes toward the Raynaud’s Condition Score diary and the perceived need for novel patient-reported outcome instruments for assessing patient-reported outcome. Nineteen Scleroderma Clinical Trials Consortium Vascular Working Group members (68% response rate) from academic units based in North America (n = 9), Europe (n = 8), South America (n = 1) and Australasia (n = 1) took part in the survey. There was broad consensus that Raynaud’s Condition Score diary returns could be influenced by factors including seasonal variation in weather, efforts made by patients to avoid or ameliorate attacks of Raynaud’s phenomenon, habituation to Raynaud’s phenomenon symptoms, evolution of Raynaud’s phenomenon symptom characteristics with progressive obliterative microangiopathy, patient-coping strategies, respondent burden and placebo effect. There was consensus that limitations of the Raynaud’s Condition Score diary might be a barrier to drug development (79% of respondents agree/strongly agree) and that a novel patient-reported outcome instrument for assessing systemic sclerosis-Raynaud’s phenomenon should be developed with the input of both clinicians and patients (84% agree/strongly agree). Perceived potential limitations of the Raynaud’s Condition Score diary have been identified along with concerns that such factors might impede drug development programs for systemic sclerosis-Raynaud’s phenomenon. There is support within the systemic sclerosis community for the development of a novel patient-reported outcome instrument for assessing systemic sclerosis-Raynaud’s phenomenon.

AB - The episodic nature of Raynaud’s phenomenon in systemic sclerosis has led to a reliance on patient-reported outcome instruments such as the Raynaud’s Condition Score diary. Little is known about the utilization in routine clinical practice and health professional attitudes toward existing patient-reported outcome instruments for assessing systemic sclerosis- Raynaud’s phenomenon. Members of the Scleroderma Clinical Trials Consortium Vascular Working Group (n = 28) were invited to participate in a survey gauging attitudes toward the Raynaud’s Condition Score diary and the perceived need for novel patient-reported outcome instruments for assessing patient-reported outcome. Nineteen Scleroderma Clinical Trials Consortium Vascular Working Group members (68% response rate) from academic units based in North America (n = 9), Europe (n = 8), South America (n = 1) and Australasia (n = 1) took part in the survey. There was broad consensus that Raynaud’s Condition Score diary returns could be influenced by factors including seasonal variation in weather, efforts made by patients to avoid or ameliorate attacks of Raynaud’s phenomenon, habituation to Raynaud’s phenomenon symptoms, evolution of Raynaud’s phenomenon symptom characteristics with progressive obliterative microangiopathy, patient-coping strategies, respondent burden and placebo effect. There was consensus that limitations of the Raynaud’s Condition Score diary might be a barrier to drug development (79% of respondents agree/strongly agree) and that a novel patient-reported outcome instrument for assessing systemic sclerosis-Raynaud’s phenomenon should be developed with the input of both clinicians and patients (84% agree/strongly agree). Perceived potential limitations of the Raynaud’s Condition Score diary have been identified along with concerns that such factors might impede drug development programs for systemic sclerosis-Raynaud’s phenomenon. There is support within the systemic sclerosis community for the development of a novel patient-reported outcome instrument for assessing systemic sclerosis-Raynaud’s phenomenon.

KW - Patient-reported outcomes

KW - Raynaud’s phenomenon

KW - Scleroderma

KW - Survey

KW - Systemic sclerosis

UR - http://www.scopus.com/inward/record.url?scp=85052556018&partnerID=8YFLogxK

U2 - 10.1177/2397198318774307

DO - 10.1177/2397198318774307

M3 - Article

VL - 3

SP - 249

EP - 252

JO - Journal of Scleroderma and Related Disorders

JF - Journal of Scleroderma and Related Disorders

SN - 2397-1983

IS - 3

ER -